Quadrant Biosciences Inc. is a collaborative effort led by company founder and CEO Richard Uhlig. Our management team has been carefully balanced to facilitate the ongoing development, testing and distribution of our products, and includes expertise in engineering, FDA regulatory compliance, production, marketing and sales. Our advisory board comprises highly regarded medical experts and data scientists.
Throughout her career, Wakaba has focused on regulatory compliance and privacy issues facing healthcare providers. Prior to joining Quadrant Biosciences, Wakaba was a Partner at Husch Blackwell LLP, an AmLaw 100 law firm. While there, Wakaba focused her practice on state and federal health privacy law, federal fraud and abuse issues related to the Stark Law, the False Claims Act and the Anti-Kickback Statute, and complex issues facing pharmacies and laboratories. She also led various business development initiatives and Associate recruiting activities on behalf of Husch Blackwell. Wakaba obtained her B.A. from Wellesley College and her J.D. from Washington University in St. Louis School of Law.
Rita Tarolli Marble
Ira Fedder, MD
David brings a biomedical engineering background to the Quadrant Biosciences research and development team. His career began in the Syracuse Biomaterials Institute developing smart-materials for wound healing applications. Since then, David has worked on projects focused on algorithm development for motion detection, as well as applying machine learning to epigenetic technologies. He has developed predictive algorithms using high-throughput sequencing data for use in the diagnosis and treatment of neurodegenerative disorders. David received his Bachelor of Science and Master’s degrees in Biomedical Engineering from Syracuse University.
Medical and Scientific Collaborators
Evdokia Anagnostou, MD
Diana L. Robins, PHD
David Beversdorf, MD
Thomas Frazier, PhD
Dr. Frazier is a licensed clinical psychologist who received his Ph.D. from Case Western Reserve University in 2004. He joined Cleveland Clinic in 2006 and from 2013-2017 was the director of the Cleveland Clinic Center for Autism. In 2017, he was hired as the Chief Science Officer at Autism Speaks, overseeing all science and service programs before joining John Carroll University in January 2020 as a Professor of Psychology. Over the last decade, Dr. Frazier has maintained an active clinical practice and research programs focused on the evaluation and treatment of autism, ADHD, and related conditions. He has published more than 120 scientific papers and has ongoing collaborations across the US and internationally.